Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share

The latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty.

See why the elites are pouring billions into gold.

Frank McCormick Biography and Net Worth

Director of BridgeBio Pharma

Frank McCormick, Ph.D. has served as a member of our Board of Directors since February 2023. He currently also serves as our Chairman of Oncology and has held this position since April 2019. He is also a Professor in the University of California, San Francisco (“UCSF”) Helen Diller Family Comprehensive Cancer Center, a multidisciplinary research and medical care organization, and has been a UCSF faculty member since 1997. Dr. McCormick has held the positions of Director of the UCSF Helen Diller Family Comprehensive Cancer Center and served as Associate Dean of the UCSF School of Medicine from 1997 to 2014. Prior to joining the UCSF faculty, Dr. McCormick pursued cancer-related work with several biotechnology firms, including Cetus Corporation as Director of Molecular Biology from 1981 to 1990 and Vice President of Research from 1990 to 1991, and Chiron Corporation as Vice President of Research from 1991 to 1992. In 1992, Dr. McCormick founded Onyx Pharmaceuticals and served as its Chief Scientific Officer until 1996. Dr. McCormick is a Fellow of the Royal Society, an institution dedicated to science, since 1996, a member of the National Academy of Sciences since 2014 and has served as President, 2012 to 2013, for the American Association for Cancer Research. Since 2013, Dr. McCormick has led the National Cancer Institute’s Ras Initiative at the Frederick National Laboratories for Cancer Research overseeing the national effort to develop therapies against Ras-driven cancers. Dr. McCormick also served as a member of the board of directors of Olema Pharmaceuticals, Inc. (Nasdaq: OLMA) from December 2014 to April 2021, and Aduro Biotech, Inc. (Nasdaq: KDNY) from 2010 to February 2019. Dr. McCormick received his B.Sc. in biochemistry from the University of Birmingham and his Ph.D. in biochemistry from the University of Cambridge and held postdoctoral fellowships in the U.S. at the State University of New York at Stony Brook and in London at the Imperial Cancer. Dr. McCormick’s qualifications to serve on our Board of Directors include his extensive scientific background, particularly in the field of oncology.

What is Frank McCormick's net worth?: The estimated net worth of Frank McCormick is at least $15.62 million as of December 26th, 2023. Dr. McCormick owns 627,689 shares of BridgeBio Pharma stock worth more than $15,616,902 as of April 28th. This net worth evaluation does not reflect any other investments that Dr. McCormick may own. Learn More about Frank McCormick's net worth.
How old is Frank McCormick?: Dr. McCormick is currently 74 years old. There are 7 older executives and no younger executives at BridgeBio Pharma. The oldest executive at BridgeBio Pharma is Dr. Charles J. Homcy M.D., Co-Founder, Chairman of Pharmaceuticals & Independent Lead Director, who is 76 years old. Learn More on Frank McCormick's age.
How do I contact Frank McCormick?: The corporate mailing address for Dr. McCormick and other BridgeBio Pharma executives is 421 Kipling Street, Palo Alto CA, 94301. BridgeBio Pharma can also be reached via phone at (650) 391-9740. Learn More on Frank McCormick's contact information.
Has Frank McCormick been buying or selling shares of BridgeBio Pharma?: Frank McCormick has not been actively trading shares of BridgeBio Pharma during the past quarter. Most recently, Frank Mccormick sold 100,000 shares of the business's stock in a transaction on Tuesday, December 26th. The shares were sold at an average price of $42.06, for a transaction totalling $4,206,000.00. Following the completion of the sale, the director now directly owns 627,689 shares of the company's stock, valued at $26,400,599.34. Learn More on Frank McCormick's trading history.
Who are BridgeBio Pharma's active insiders?: BridgeBio Pharma's insider roster includes Douglas Dachille (Director), Ronald Daniels (Director), Neil Kumar (CEO), Frank McCormick (Director), Richard Scheller (Insider), Randal Scott (Director), Brian Stephenson (CFO), and Hannah Valantine (Director). Learn More on BridgeBio Pharma's active insiders.
Are insiders buying or selling shares of BridgeBio Pharma?: In the last year, insiders at the sold shares 9 times. They sold a total of 1,757,626 shares worth more than $60,168,484.96. The most recent insider tranaction occured on March, 1st when Director Randal W Scott sold 2,500 shares worth more than $85,000.00. Insiders at BridgeBio Pharma own 28.5% of the company. Learn More about insider trades at BridgeBio Pharma.
Information on this page was last updated on 3/1/2024.

Frank McCormick Insider Trading History at BridgeBio Pharma

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/26/2023	Sell	100,000	$42.06	$4,206,000.00	627,689
12/30/2019	Sell	17,150	$35.80	$613,970.00	1,335,895
12/27/2019	Sell	82,850	$37.92	$3,141,672.00	1,335,895

Frank McCormick Buying and Selling Activity at BridgeBio Pharma

BridgeBio Pharma Company Overview

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

Today's Range

Now: $24.88

$24.32

$24.99

50 Day Range

MA: $29.42

$24.33

$37.21

2 Week Range

Now: $24.88

$12.75

$44.32

Volume

1,049,219 shs

Average Volume

1,507,542 shs

Market Capitalization

$4.37 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.03

Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share

From Colonial Metals | Ad